VUB spin-off Precirix, the clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, discloses that they signed an agreement with Eckert & Ziegler for the supply of Actinium-225. Actinium-225 is used as an active substance in cancer treatment. The precise treatment of tumor cells, including elusive micrometastases, is enabled by this radioisotope.